It's been a busy few weeks for US pharma giant Mylan, which reports quarterly earnings today. Firstly, it made a proposal to buy Dublin-based Perrigo, in a deal valued at approximately $29 billion.

Then, it received a takeover approach from Teva Pharmaceuticals, which proposed to acquire Mylan for $40 billion. The takeover approach came after weeks of speculation that Teva, the world's largest generic company, would make a bid for Mylan. The combined company would have annual revenue of $30 billion, and Teva said it would expect $2 billion in cost savings within three years.

Mylan shares soared last week on the back of the proposal, which is the largest takeover attempt in the drug industry this year.

Mylan last issued its quarterly earnings data on March 2nd. The company had revenue of $2.08 billion for the quarter, compared to the consensus estimate of $2.07 billion. Its revenue was up 15.1 per cent compared to the same quarter last year.

The company reported $1.05 earnings per share for the quarter, meeting the analysts’ consensus estimate of $1.05.

Analysts expect that Mylan will post $4.14 EPS for the current fiscal year.